Quarterly Results

Date Title and Summary
Toggle Summary POZEN Reports Second Quarter Profit; Results Reflect $20 Million Milestone Payment For VIMOVO(TM)
Company Focused on Strategic Roadmap for Commercialization of PA Product Portfolio CHAPEL HILL, N.C., Aug 03, 2010 (BUSINESS WIRE) -- POZEN Inc. (NASDAQ:POZN) , a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended
Toggle Summary Aralez Reports Fourth Quarter And Full-Year 2015 Results
- Announced Today the Resubmission to the FDA of the NDA for YOSPRALA™- - Expects 2016 Net Revenues to be in a Range of $48 Million to $58 Million - MILTON, Ontario , March 15, 2016 /PRNewswire/ --  Aralez Pharmaceuticals Inc.   (NASDAQ: ARLZ) (TSX: ARZ) (" Aralez " or the " Company "), today
Toggle Summary Aralez Reports First Quarter 2016 Financial Results
-First Quarter 2016 Includes the Operations of Tribute from February 5, 2016 through March 31, 2016 - MILTON, Ontario , May 10, 2016 /PRNewswire/ --   Aralez Pharmaceuticals Inc.   (NASDAQ: ARLZ) (TSX: ARZ) (" Aralez " or the " Company "), today announced financial results for the first quarter
Toggle Summary Aralez Announces Voting Results From 2016 Annual General Meeting Of Shareholders
MISSISSAUGA, Ontario , June 16, 2016 /PRNewswire/ --  Aralez Pharmaceuticals Inc.   (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), today announced the results of the matters voted upon at the Company's 2016 annual general meeting (the "Meeting") of shareholders (the "Shareholders") held

Copyright West LLC. Minimum 15 minutes delayed.